NH1,902.90

Narayana Hrudayalaya Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISNEULANDLABNATCOPHARMLALPATHLABSAILIFECOHANCEMcap ₹38,888 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+9.3+44.0
EBITDA Growth+10.8+26.7
EBIT Growth+9.7+17.1
Net Income Growth+0.1+1.9
EPS Growth+0.1+2.0
Total Assets Growth+29.2+71.7
Total Equity Growth+25.8+25.1
Cash from Operations Growth-7.2+63.5
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.